Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | DDO | Q99489 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2209444 | 0.98 | HTR2C (0.48) | MAOBBRD4DAODDOHTR2C | |
| Hydrochloric Acid SCHEMBL31318331 | 0.98 | HTR2C (0.48) | MAOBBRD4DAODDOHTR2C | |
| SCHEMBL29151429 | 0.94 | PARP1 (0.44) | MAOBBRD4DAODDOHTR2C | |
| SCHEMBL30747837 | 0.94 | PARP1 (0.44) | MAOBBRD4DAODDOHTR2C | |
| SCHEMBL27792401 | 0.90 | DAO (0.53) | BRD4DAODDOKDRCHEK1 | |
| SCHEMBL677495 | 0.87 | BRD4 (0.50) | BRD4DAODDOKDRCHEK1 | |
| SCHEMBL14540060 | 0.84 | BRD4 (0.47) | BRD4DAODDOKDRCHEK1 | |
| SCHEMBL7004929 | 0.83 | BRD4 (0.46) | BRD4DAODDOKDRCHEK1 | |
| SCHEMBL24781820 | 0.81 | DAO (0.51) | DAOHTR2CCHEK1CA12CA9 | |
| SCHEMBL12512954 | 0.81 | DAO (0.51) | DAOCHEK1GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025125353-A1 | METHOD OF PREPARATION OF ZAVEGEPANT, SYNTHESIS INTERMEDIATES OF ZAVEGEPANT AND METHODS OF PREPARATION THEREOF | MOEHS IBERICA, S.L. (ES) | 2025-06-19 | — | — | WO | claimed |
| CN-121293184-A | Preparation method of 3- (piperidin-4-yl) quinolin-2 (1H) -one | 江苏工程职业技术学院 | 2026-01-09 | — | — | CN | disclosed |
| WO-2025125353-A1 | METHOD OF PREPARATION OF ZAVEGEPANT, SYNTHESIS INTERMEDIATES OF ZAVEGEPANT AND METHODS OF PREPARATION THEREOF | MOEHS IBERICA, S.L. (ES) | 2025-06-19 | — | — | WO | disclosed |
| US-12178813-B2 | CGRP receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2024-12-31 | — | — | US | disclosed |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | PFIZER IRELAND PHARMACEUTICALS | 2024-12-12 | — | — | US | disclosed |
| US-12030868-B2 | Prodrugs of CGRP antagonists | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-07-09 | — | — | US | disclosed |
| CN-117551081-A | New preparation method of migraine therapeutic drug | 北京康立生医药技术开发有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4284505-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | Pfizer Ireland Pharmaceuticals (IE) | 2023-12-06 | — | — | EP | disclosed |
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-12-22 | — | — | US | disclosed |
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-12-22 | — | — | US | disclosed |
| US-20050215576-A1 | Novel therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-29 | — | — | US | disclosed |
| US-20050153959-A1 | 3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one; small molecule; non-peptidic; antagonists of calcitonin gene-related peptide receptors (\"CGRP-receptor\"); neurogenic vasodilation and inflammation, cluster headache | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005056550-A2 | HETEROCYCLIC ANTI-MIGRAINE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2004091514-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| CN-1129605-C | Modified aminoacids, pharmaceuticals containing these compounds and method for their prodn. | THOMAE GMBH DR K (DE) | 2003-12-03 | — | — | CN | disclosed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| EP-0755392-A4 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0755392-A1 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028397-A1 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | CALCA, CALCB, CALCRL | MAOB 245/4885BRD4 1511/4885DAO 3797/4885 |
| US-12030868-B2 | Prodrugs of CGRP antagonists | CALCRL, CALCA, CALCB | MAOB 484/4885BRD4 2969/4885DAO 1378/4885 |
| US-20050153959-A1 | 3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one; small molecule; non-peptidic; antagonists of calcitonin gene-related peptide receptors (\"CGRP-receptor\"); neurogenic vasodilation and inflammation, cluster headache | CALCRL, CALCA, BDKRB2 | MAOB 1524/4885BRD4 373/4885DAO 4495/4885 |
| US-20050215576-A1 | Novel therapeutic agents for the treatment of migraine | CALCRL, CALCR, CALCA | MAOB 630/4885BRD4 1473/4885DAO 4439/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | MAOB 64/4885BRD4 4811/4885DAO 7/4885 |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | CALCA, CALCB, CALCRL | MAOB 319/4885BRD4 2407/4885DAO 3893/4885 |
| US-12178813-B2 | CGRP receptor antagonists | CALCRL, CALCR, VIPR1 | MAOB 903/4885BRD4 1119/4885DAO 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.